File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.yjmcc.2010.03.009
- Find via
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Effects of abacavir on the vascular and platelet activities
Title | Effects of abacavir on the vascular and platelet activities |
---|---|
Authors | |
Issue Date | 2010 |
Publisher | Academic Press. The Journal's web site is located at http://www.elsevier.com/locate/yjmcc |
Citation | The 20th World Congress of the International Society for Heart Research (ISHR 2010), Kyoto, Japan, 13-16 May 2010. In Journal of Molecular and Cellular Cardiology, v. 48 n. 5 suppl. 1, abstract no. P-2-18-6 How to Cite? |
Abstract | Abacavir is an antiviral nucleoside analogue effectively used
to treat HIV infection. However, a study showed that the use
of abacavir significantly increased the risks of stroke and
myocardial infraction. We sought to investigate the effects of
abacavir on vascular and platelet activities so as to understand
the underlying mechanisms. Sprague-Dawley rats (330-350 g)
were fed with abacavir (16 mg/kg/day, equivalent to the
clinical dosage on human) for 28 days by gastric gavage.
Isometric tensions of basilar arteries were measured. Aorta
mRNA and proteins expressions of various factors related to
endothelial function and inflammation were measured by
RT-PCR and Western blotting, respectively. To measure the
effect of abacavir on platelet activation, the plasma levels of
CD40L, a platelet-derived factor which is released upon
platelet activation, were measured by ELISA kit. Our results
showed that abacavir treatment did not affect the maximum
relaxation response of basilar artery. Besides, there were no
significant change in the mRNA and protein expression levels
of eNOS, COX-1, COX-2 and ICAM-1 in aorta after abacavir
treatment. However, a higher plasma level of CD40L was
detected in the abacavir-treated group. It is suggested that
abacavir does not affect vascular contractility nor induced
endothelial inflammation. However, abacavir upregulates the
platelet activity, which will theoretically increase the chance of
developing thrombosis. This may be a possible explanation for
the higher risk of cardiovascular events in patients receiving
abacavir treatment. |
Persistent Identifier | http://hdl.handle.net/10722/202385 |
ISSN | 2023 Impact Factor: 4.9 2023 SCImago Journal Rankings: 1.639 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Li, RWS | - |
dc.contributor.author | Kwan, SYW | - |
dc.contributor.author | Leung, GPH | - |
dc.date.accessioned | 2014-09-18T06:13:16Z | - |
dc.date.available | 2014-09-18T06:13:16Z | - |
dc.date.issued | 2010 | - |
dc.identifier.citation | The 20th World Congress of the International Society for Heart Research (ISHR 2010), Kyoto, Japan, 13-16 May 2010. In Journal of Molecular and Cellular Cardiology, v. 48 n. 5 suppl. 1, abstract no. P-2-18-6 | - |
dc.identifier.issn | 0022-2828 | - |
dc.identifier.uri | http://hdl.handle.net/10722/202385 | - |
dc.description.abstract | Abacavir is an antiviral nucleoside analogue effectively used to treat HIV infection. However, a study showed that the use of abacavir significantly increased the risks of stroke and myocardial infraction. We sought to investigate the effects of abacavir on vascular and platelet activities so as to understand the underlying mechanisms. Sprague-Dawley rats (330-350 g) were fed with abacavir (16 mg/kg/day, equivalent to the clinical dosage on human) for 28 days by gastric gavage. Isometric tensions of basilar arteries were measured. Aorta mRNA and proteins expressions of various factors related to endothelial function and inflammation were measured by RT-PCR and Western blotting, respectively. To measure the effect of abacavir on platelet activation, the plasma levels of CD40L, a platelet-derived factor which is released upon platelet activation, were measured by ELISA kit. Our results showed that abacavir treatment did not affect the maximum relaxation response of basilar artery. Besides, there were no significant change in the mRNA and protein expression levels of eNOS, COX-1, COX-2 and ICAM-1 in aorta after abacavir treatment. However, a higher plasma level of CD40L was detected in the abacavir-treated group. It is suggested that abacavir does not affect vascular contractility nor induced endothelial inflammation. However, abacavir upregulates the platelet activity, which will theoretically increase the chance of developing thrombosis. This may be a possible explanation for the higher risk of cardiovascular events in patients receiving abacavir treatment. | - |
dc.language | eng | - |
dc.publisher | Academic Press. The Journal's web site is located at http://www.elsevier.com/locate/yjmcc | - |
dc.relation.ispartof | Journal of Molecular and Cellular Cardiology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.title | Effects of abacavir on the vascular and platelet activities | en_US |
dc.type | Conference_Paper | en_US |
dc.identifier.email | Li, RWS: lirws@hku.hk | - |
dc.identifier.email | Leung, GPH: gphleung@hku.hk | - |
dc.description.nature | postprint | - |
dc.identifier.doi | 10.1016/j.yjmcc.2010.03.009 | - |
dc.identifier.hkuros | 170531 | - |
dc.identifier.volume | 48 | - |
dc.identifier.issue | 5 suppl. 1 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 0022-2828 | - |